HY-P99235-1mg
|
MedChemexpress LLC
|
Nadunolimab
|
|
Cancer-programmed cell death
|
|
HY-P99235-10mg
|
MedChemexpress LLC
|
Nadunolimab
|
|
Cancer-programmed cell death
|
|
HY-P99235-5mg
|
MedChemexpress LLC
|
Nadunolimab
|
|
Cancer-programmed cell death
|
|
HY-P99376-1mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
HY-P99376-10mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
HY-P99376-5mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
HY-P9903A-1mg
|
MedChemexpress LLC
|
Nivolumab (anti-PD-1) [CAS 946414-94-4]
|
|
Cancer-programmed cell death
|
|
HY-P9903A-5mg
|
MedChemexpress LLC
|
Nivolumab (anti-PD-1) [CAS 946414-94-4]
|
|
Cancer-programmed cell death
|
|
HY-P9903-1mg
|
MedChemexpress LLC
|
Nivolumab [CAS 946414-94-4]
|
|
Cancer-programmed cell death
|
|
HY-P9903-25mg
|
MedChemexpress LLC
|
Nivolumab [CAS 946414-94-4]
|
|
Cancer-programmed cell death
|
|
HY-P9903-5mg
|
MedChemexpress LLC
|
Nivolumab [CAS 946414-94-4]
|
|
Cancer-programmed cell death
|
|
HY-P9903-50mg
|
MedChemexpress LLC
|
Nivolumab [CAS 946414-94-4]
|
|
Cancer-programmed cell death
|
|
HY-P9932-1mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
HY-P9932-10mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
HY-P9932-5mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
HY-P9961-1mg
|
MedChemexpress LLC
|
OfatuMu mab [CAS 679818-59-8]
|
|
Cancer-programmed cell death
|
|
HY-P9961-10mg
|
MedChemexpress LLC
|
OfatuMu mab [CAS 679818-59-8]
|
|
Cancer-programmed cell death
|
|
HY-P9961-5mg
|
MedChemexpress LLC
|
OfatuMu mab [CAS 679818-59-8]
|
|
Cancer-programmed cell death
|
|
HY-P99039-1mg
|
MedChemexpress LLC
|
Oleclumab [CAS 1803176-05-7]
|
|
Cancer-programmed cell death
|
|
HY-P99039-5mg
|
MedChemexpress LLC
|
Oleclumab [CAS 1803176-05-7]
|
|
Cancer-programmed cell death
|
|
HY-P99157-1mg
|
MedChemexpress LLC
|
Omburtamab [CAS 1895083-75-6]
|
|
Cancer-programmed cell death
|
|
HY-P99157-10mg
|
MedChemexpress LLC
|
Omburtamab [CAS 1895083-75-6]
|
|
Cancer-programmed cell death
|
|
HY-P99157-5mg
|
MedChemexpress LLC
|
Omburtamab [CAS 1895083-75-6]
|
|
Cancer-programmed cell death
|
|
HY-P99040-1mg
|
MedChemexpress LLC
|
Onvatilimab [CAS 1969313-51-6]
|
|
Cancer-programmed cell death
|
|
HY-P99040-5mg
|
MedChemexpress LLC
|
Onvatilimab [CAS 1969313-51-6]
|
|
Cancer-programmed cell death
|
|